Wish To Hasten Death: a clinical vision of a new-old syndrome?
WeCare Chair. Universitat Internacional de Catalunya.
Barcelona, 29-30 November 2013
- To contribute to disseminate the concept and current knowledge about the WTHD among interested professionals and persons on the subject.
- To foster a network of clinicians and researchers interested in the clinical aspects of End-of-Life Care.
- To discuss and share the current knowledge on WTHD in patients with advanced illness.
- To explore possibilities and opportunities of a European study on WTHD with international partnerships.
Friday, 29th November
|10:30|| Presentation WeCare
Chairs the Honorable Minister of Health of theGeneralitat de Catalunya, Mr. Boi Ruiz
|11:00||Coffee Break with Presentation’s assistants|
|11:30|| Wish to Hasten Death (WTHD): state of art
what can it mean for the patient who express it.Wish to Hasten Death: results of a Metaethnography
|Dr. Cristina Monforte|
|11:50||Results of a recent study in palliative care: WTHD and survival Results SeViDAM||Mr. Christian Villavicencio|
|WTHD and MIL a model Results SeViDAM||Dr. Steffi Lichtenfeldand Dr. Cristina Monforte|
|12:30||Discussion & questions||Dr. Albert Balaguer and Dr. Markus Meier (moderators)|
|14:00||WTHD: from the philosophical point of viewAttitudes towards, and wishes for euthanasia in advanced cancer patients.||Dr. Lars Matersdvedt|
|14:20||WTHD: from the clinical point of viewEthics in end of life issues and decission making||Dr. Chris Gastmans|
|14:40||Discussion &questions||Dr. Lars Matersdvedt and Dr. Chris Gastmans|
|15:40||Wish to Hasten Death: from the sociological point of view Medical end-of-life decisions: does its use differ in vulnerable patient groups?||Dr. Luc Deliens|
|15:55||Wish to Hasten Death: from the clinical point of viewIssues of “life” and “death” for patients receiving palliative care||Dr. Alberto Alonso|
|16:10||Pendiente de confirmación título conferencia||Dr. Gerrit Frerich|
|16:25||Discussion & questions||Dr. Luc Deliens and Dr. Alberto Alonso|
|16:50|| General discussion and comments
|Dr. Albert Balaguer, Dr. Josep Porta and Dr. Cristina Monforte|